NCT01024894View on ClinicalTrials.gov

Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in Asiatic HCV Patients Resistant to Bitherapy

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

November 30, 2012

Study Completion Date

December 31, 2012

Conditions
Hepatitis C
Interventions
DRUG

Interleukin-7

3 dose levels: 3, 10 \& 20 µg/kg. 4 administrations, 1 per week

Trial Locations (4)

807

Kaohsiung Medical University Hospital, Kaohsiung City

10650

Cathay General Hospital, Taipei

33305

Chang Gung Memorial Hospital, Taipei

Unknown

Chi Mei Medical Center, Tainan City

Sponsors

Lead Sponsor

Cytheris SA
All Listed Sponsors
lead

Cytheris SA

INDUSTRY